Unresectable Extrahepatic Bile Duct Cancer Withdrawn Phase 2 Trials for Selumetinib (DB11689)

IndicationStatusPhase
DBCOND0028791 (Unresectable Extrahepatic Bile Duct Cancer)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01859182Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By SurgeryTreatment